Authors: Joey Rehkopf, Nikolas Richter, Maud Brijs, Kristof Theys, Malte Glüsen, Matthias P. Schönermark
Monday 10th Nov 2025
Poster Presentation: 16:00 – 19:00
Discussion Period: 18:00 – 19:00
OBJECTIVES
This research explores how German ATMP prices compare to those in other major European markets. The aim was to analyse changes in the pricing strategy of ATMPs in Germany from the payer’s perspective over the recent years, as well as to compare it with other European countries such as France, Ireland, Netherlands and UK.
METHODS
A comparative data analysis of the German list prices was conducted for all ATMPs after successful price negotiations based on the Lauer Taxe and a proprietary AMNOG database, including a peer group analysis based on several factors such as population size or granted added benefit. Afterwards, the findings were compared with the prices in other European countries. If no rebated prices were available for the other countries, ex-factory prices were compared.
RESULTS
The net prices of the 14 ATMPs that underwent the AMNOG process and still hold their marketing authorisation ranged between ~€30,000 up to €3,000,000 with an average of €551,557.57. In general, the net prices were lower for ATPMs with several indication extensions and therefore higher total target populations. Net prices after negotiation also correlate with the grade of the granted additional benefit with rebates ranging from ~3.55% up to 52.4% with a mean rebate of 16.4%. Ex-factory price levels were similar between Germany, Ireland, France and the Netherlands, with some exceptions in the UK, where (adjusted) price levels were in some cases higher than average.
CONCLUSIONS
Based on the payer decisions and AMNOG precedents on ATMPs, there is no clear trend or change on pricing decisions over the recent years. Comparisons with other EU countries show, that Germany is still a leading price anchor for ATMPs and often used for reference pricing.
